Derwood Pamphilon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Derwood Pamphilon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Anneke Brand
Department of Transfusion Medicine, Sanquin Blood Bank, Amsterdam, the Netherlands
1 shared publication Biomedical Excellence for Safer Transfusion (BEST) Collaborative
1 shared publication- Carolyn Doree
Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK
1 shared publication Chris Hyde
Systematic Review Initiative, NHS Blood and Transplant, Oxford Centre, Oxford, UK
1 shared publicationCristina Navarrete
From the British Bone Marrow Registry and Institute for Transfusion Sciences, Bristol; Academic Haematology, Royal Free and University College London Medical Schools, London; and Anthony Nolan Trust, London, UK
1 shared publicationDavid H. McKenna
From the Leiden Cord Bloodbank, Sanquin, the Netherlands; the Mannheim Cord Bloodbank, Mannheim, Germany; Dartmouth‐Hitchcock Medical Center, Lebanon, New Hampshire; Puget Sound Blood Center, Seattle, Washington; Hoxworth Blood Center, Cincinnati, Ohio; University of Maryland, Baltimore, Maryland; Institute of Medical Science, Tokyo, Japan; Red Cross Blood Service, Helsinki, Finland; University of Minnesota, St Paul, Minnesota; and NBS, Bristol, UK
1 shared publication
Latest Publications
- 19 August 2011
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 29 (9) , 1322-1326
Concise Review: Expanding Roles for Hematopoietic Cellular Therapy and the Blood Transfusion Services
Hematopoietic stem cells (HSCs) have remained at the forefront of stem cell research for the past 50 years, since the therapeutic potential of bone marrow transplantation was realized. Uniquely, among stem and progenitor cells, research progress has been made in parallel between the laboratory benchtop and hospital bedside during this period. Integral to this work has been the role of the transfusion medicine services in the collection, storage, and processing of HSCs. The next decade promises to bring further developments: with new fields of cellular therapies, stem cell vaccination, and stem cell drug testing opening up. This article summarizes exciting areas of research concerning the behavior and potential clinical applications of HSCs. For the purposes of clarity, we describe in turn the trafficking and transfer of HSCs; ex vivo expansion of HSC units from different sources; and finally, applications of specifically selected subsets of hematopoietic cells and their progeny.
- 19 August 2011
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 29 (9) , 1322-1326
Concise Review: Expanding Roles for Hematopoietic Cellular Therapy and the Blood Transfusion Services
Hematopoietic stem cells (HSCs) have remained at the forefront of stem cell research for the past 50 years, since the therapeutic potential of bone marrow transplantation was realized. Uniquely, among stem and progenitor cells, research progress has been made in parallel between the laboratory benchtop and hospital bedside during this period. Integral to this work has been the role of the transfusion medicine services in the collection, storage, and processing of HSCs. The next decade promises to bring further developments: with new fields of cellular therapies, stem cell vaccination, and stem cell drug testing opening up. This article summarizes exciting areas of research concerning the behavior and potential clinical applications of HSCs. For the purposes of clarity, we describe in turn the trafficking and transfer of HSCs; ex vivo expansion of HSC units from different sources; and finally, applications of specifically selected subsets of hematopoietic cells and their progeny.
- 6 December 2010
- Published by Wiley in Transfusion
- Vol. 51 (6) , 1284-1290
Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative
BACKGROUND: Most hematopoietic progenitor cell (HPC) products are infused or processed shortly after collection, but in some cases this may be delayed for up to 48 hours. A number of variables such as temperature and cell concentration are of critical importance for the integrity of HPCs during this time.STUDY DESIGN AND METHODS: We evaluated critical variables using cord blood HPC units that were divided equally and stored at 4°C versus room temperature (RT) for up to 96 hours. Total nucleated cell (TNC) and mononuclear cell (MNC) counts, viable CD34+ cell counts, and CD45+ cell viability as well as colony‐forming unit–granulocyte‐macrophage (CFU‐GM) present over time at each temperature were determined.RESULTS: Overall, the data indicate that with the exception of viable CD34+ cells, there was a significant decrease in each variable measured for 72 to 96 hours and, with the exception of viable CD34+ cells and CFU‐GM, the reductions were significantly greater in RT units than 4°C units. There was an increase in viable CD34+ count for units where TNC count was greater than 8.5 × 109/L, compared with units where TNC count was less than 8.5 × 109/L, that was different for each storage temperature.CONCLUSIONS: Cord blood HPC collections maintained at 4°C retained higher TNC counts, MNC counts, and CD45+ cell viability over a 72‐ to 96‐hour storage period.
- 6 December 2010
- Published by Wiley in Transfusion
- Vol. 51 (6) , 1284-1290
Storage characteristics of cord blood progenitor cells: report of a multicenter study by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative
BACKGROUND: Most hematopoietic progenitor cell (HPC) products are infused or processed shortly after collection, but in some cases this may be delayed for up to 48 hours. A number of variables such as temperature and cell concentration are of critical importance for the integrity of HPCs during this time.STUDY DESIGN AND METHODS: We evaluated critical variables using cord blood HPC units that were divided equally and stored at 4°C versus room temperature (RT) for up to 96 hours. Total nucleated cell (TNC) and mononuclear cell (MNC) counts, viable CD34+ cell counts, and CD45+ cell viability as well as colony‐forming unit–granulocyte‐macrophage (CFU‐GM) present over time at each temperature were determined.RESULTS: Overall, the data indicate that with the exception of viable CD34+ cells, there was a significant decrease in each variable measured for 72 to 96 hours and, with the exception of viable CD34+ cells and CFU‐GM, the reductions were significantly greater in RT units than 4°C units. There was an increase in viable CD34+ count for units where TNC count was greater than 8.5 × 109/L, compared with units where TNC count was less than 8.5 × 109/L, that was different for each storage temperature.CONCLUSIONS: Cord blood HPC collections maintained at 4°C retained higher TNC counts, MNC counts, and CD45+ cell viability over a 72‐ to 96‐hour storage period.
- 14 July 2010
- Published by Wiley in Vox Sanguinis
- Vol. 99 (2) , 168-173
Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative
Background and Objectives Most cell therapy products (CTP) are infused or processed shortly after collection but in some cases this may be delayed for up to 48 h. A number of variables such as temperature and cell concentration are of critical importance for the integrity of CTP during this time. Materials and Methods We conducted a survey of cellular therapy laboratories to ascertain current practices for CTP transportation. Results There were 194 respondents of whom 90% shipped or received CTP – 84% allogeneic, 71% autologous and 62% therapeutic cells. Processing facilities shipped or received the following products – hematopoietic progenitor cells (HPC), Marrow 73%; HPC, Apheresis 90%; HPC, Cord Blood 54% and others 14%. Other CTP included donor lymphocytes, mesenchymal stem cells (MSC), natural killer cells, buffy coat neutrophils and virus-specific cytotoxic T lymphocytes (CTL). More than 70% of respondents believed that it was acceptable for CTP to be held for up to 2 h without checking the temperature or cell density and a similar proportion agreed that putting products in containers to control parameters such as temperature within this time period was unnecessary. The majority of centres shipped or received between 1 and 10 CTP annually and 66% received products taking more than 2 h to ship. Of these, 82% specified the conditions for temperature in transit whilst 57% monitored temperature in transit and 74% of these used a data logger. The temperature range most commonly specified was 18–24°C. The majority of processing facilities did not request an adjustment to the cell density even for products taking more than 2 h to reach their facility. More than 90% of respondents tested HPC for CD34+ cells, viability and sterility; 40–48% performed colony-forming unit–granulocyte macrophage (CFU–GM) analysis. Only viability was thought by > 50% of respondents to be impacted by temperature, cell density and other parameters. Conclusion Understanding current practice will help in the design of future studies for CTP storage and transportation.
- 14 July 2010
- Published by Wiley in Vox Sanguinis
- Vol. 99 (2) , 168-173
Transportation of cellular therapy products: report of a survey by the cellular therapies team of the Biomedical Excellence for Safer Transfusion (BEST) collaborative
Background and Objectives Most cell therapy products (CTP) are infused or processed shortly after collection but in some cases this may be delayed for up to 48 h. A number of variables such as temperature and cell concentration are of critical importance for the integrity of CTP during this time. Materials and Methods We conducted a survey of cellular therapy laboratories to ascertain current practices for CTP transportation. Results There were 194 respondents of whom 90% shipped or received CTP – 84% allogeneic, 71% autologous and 62% therapeutic cells. Processing facilities shipped or received the following products – hematopoietic progenitor cells (HPC), Marrow 73%; HPC, Apheresis 90%; HPC, Cord Blood 54% and others 14%. Other CTP included donor lymphocytes, mesenchymal stem cells (MSC), natural killer cells, buffy coat neutrophils and virus-specific cytotoxic T lymphocytes (CTL). More than 70% of respondents believed that it was acceptable for CTP to be held for up to 2 h without checking the temperature or cell density and a similar proportion agreed that putting products in containers to control parameters such as temperature within this time period was unnecessary. The majority of centres shipped or received between 1 and 10 CTP annually and 66% received products taking more than 2 h to ship. Of these, 82% specified the conditions for temperature in transit whilst 57% monitored temperature in transit and 74% of these used a data logger. The temperature range most commonly specified was 18–24°C. The majority of processing facilities did not request an adjustment to the cell density even for products taking more than 2 h to reach their facility. More than 90% of respondents tested HPC for CD34+ cells, viability and sterility; 40–48% performed colony-forming unit–granulocyte macrophage (CFU–GM) analysis. Only viability was thought by > 50% of respondents to be impacted by temperature, cell density and other parameters. Conclusion Understanding current practice will help in the design of future studies for CTP storage and transportation.
- Open Access
- 14 September 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (1) , 71-76
Stem cell donation – What advice can be given to the donor?
Haematopoietic stem cell transplantation (HSCT) is widely used to treat patients with a range of haematological and non‐haematological disorders. Both bone marrow and peripheral blood stem cell collection are associated with morbidity and, very rarely, mortality. We investigated the information that exists to adequately inform donors about the relative merits of each procedure. We carried out a systematic review analysing data from six prospective randomised controlled trials of related donors and discuss here the merits and drawbacks of this approach. Registry data mostly describes patient outcome but stem cell donor registries collect and report information on unrelated donors which could easily be extended to related donors. Further well‐designed, randomised studies are required.
- 14 September 2009
- Published by Wiley in British Journal of Haematology
- Vol. 147 (1) , 71-76
Open AccessStem cell donation – What advice can be given to the donor?
Haematopoietic stem cell transplantation (HSCT) is widely used to treat patients with a range of haematological and non‐haematological disorders. Both bone marrow and peripheral blood stem cell collection are associated with morbidity and, very rarely, mortality. We investigated the information that exists to adequately inform donors about the relative merits of each procedure. We carried out a systematic review analysing data from six prospective randomised controlled trials of related donors and discuss here the merits and drawbacks of this approach. Registry data mostly describes patient outcome but stem cell donor registries collect and report information on unrelated donors which could easily be extended to related donors. Further well‐designed, randomised studies are required.
- Open Access
- 13 February 2009
- Published by Wiley in ISBT Science Series
- Vol. 4 (1) , 24-30
Quality approaches in cell therapy: patient and therapy-related aspects
- 13 February 2009
- Published by Wiley in ISBT Science Series
- Vol. 4 (1) , 24-30
Open AccessQuality approaches in cell therapy: patient and therapy-related aspects
- 8 July 2008
- Published by Wiley in Transfusion
- Vol. 48 (7) , 1495-1501
The use of granulocyte–colony‐stimulating factor in volunteer unrelated hemopoietic stem cell donors
Granulocyte–colony‐stimulating factor (G‐CSF) is used for the mobilization of hemopoietic stem cells in healthy donors. It has a number of common side effects such as bone pain, which resolve rapidly after administration is discontinued. Recent publications have raised concern that it might act as a trigger for the development of hematologic malignancy in susceptible individuals, possibly by causing genomic instability, but to date there is no evidence that healthy volunteer donors who receive G‐CSF are at any increased risk. Ongoing studies aim to confirm whether or not G‐CSF can cause chromosomal abnormalities in healthy donors. In the UK, the British Bone Marrow Registry and Anthony Nolan Trust give G‐CSF to donors who have agreed to donate peripheral blood stem cells. It is recommended by the UK Registries at present that all stem cell donors are given updated information explaining the current uncertainties with regard to the use of G‐CSF before they give informed consent to its administration. This information is based on a statement agreed by the World Marrow Donor Association for use by individual donor registries. Further, it is our current practice that all donors who have received G‐CSF, as well as marrow donors who do not, should be under regular review for at least 10 years to allow the occurrence of any long‐term adverse events to be documented.
- 8 July 2008
- Published by Wiley in Transfusion
- Vol. 48 (7) , 1495-1501
The use of granulocyte–colony‐stimulating factor in volunteer unrelated hemopoietic stem cell donors
Granulocyte–colony‐stimulating factor (G‐CSF) is used for the mobilization of hemopoietic stem cells in healthy donors. It has a number of common side effects such as bone pain, which resolve rapidly after administration is discontinued. Recent publications have raised concern that it might act as a trigger for the development of hematologic malignancy in susceptible individuals, possibly by causing genomic instability, but to date there is no evidence that healthy volunteer donors who receive G‐CSF are at any increased risk. Ongoing studies aim to confirm whether or not G‐CSF can cause chromosomal abnormalities in healthy donors. In the UK, the British Bone Marrow Registry and Anthony Nolan Trust give G‐CSF to donors who have agreed to donate peripheral blood stem cells. It is recommended by the UK Registries at present that all stem cell donors are given updated information explaining the current uncertainties with regard to the use of G‐CSF before they give informed consent to its administration. This information is based on a statement agreed by the World Marrow Donor Association for use by individual donor registries. Further, it is our current practice that all donors who have received G‐CSF, as well as marrow donors who do not, should be under regular review for at least 10 years to allow the occurrence of any long‐term adverse events to be documented.
- 1 March 2008
- Published by Wiley in Transfusion
- Vol. 48 (3) , 546-549
Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise
Clinical transplant outcome with umbilical cord blood (UCB) as source of hematopoietic progenitor cells (HPCs) is, among other factors, determined by the total number of viable nucleated cells and/or CD34+ cells in the unit. Quantitative and qualitative losses by processing and cryopreservation and by thawing and washing before transfusion may occur, however. Another reason for a discrepancy between the number of cells in the unit released by the cord blood bank and found in the transplant center may be technical differences in cell counting methods between the two sites.With the collaborative group for Biomedical Excellence for Safer Transfusion (BEST), an interlaboratory exercise was conducted among nine sites for thawed UCB variables: total nucleated cells, CD34+ cells, viability, and HPC cultures. Three frozen UCB samples were shipped, with instructions for thawing, counting, and HPC plating.Unexpectedly samples arrived at all nine receiving centers without detectable hematopoietic progenitor colony-forming cells. Nevertheless, wide interlaboratory ranges for viability were obtained. The proportion of viable cells was found higher with manual methods, but all viability assays used in the study overestimated functional progenitor cells.The results underscore the complexity of evaluation of frozen-thawed cord blood cells and the need for standardization of assessment.
- 1 March 2008
- Published by Wiley in Transfusion
- Vol. 48 (3) , 546-549
Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise
Clinical transplant outcome with umbilical cord blood (UCB) as source of hematopoietic progenitor cells (HPCs) is, among other factors, determined by the total number of viable nucleated cells and/or CD34+ cells in the unit. Quantitative and qualitative losses by processing and cryopreservation and by thawing and washing before transfusion may occur, however. Another reason for a discrepancy between the number of cells in the unit released by the cord blood bank and found in the transplant center may be technical differences in cell counting methods between the two sites.With the collaborative group for Biomedical Excellence for Safer Transfusion (BEST), an interlaboratory exercise was conducted among nine sites for thawed UCB variables: total nucleated cells, CD34+ cells, viability, and HPC cultures. Three frozen UCB samples were shipped, with instructions for thawing, counting, and HPC plating.Unexpectedly samples arrived at all nine receiving centers without detectable hematopoietic progenitor colony-forming cells. Nevertheless, wide interlaboratory ranges for viability were obtained. The proportion of viable cells was found higher with manual methods, but all viability assays used in the study overestimated functional progenitor cells.The results underscore the complexity of evaluation of frozen-thawed cord blood cells and the need for standardization of assessment.